Vanta Bioscience Ltd
VANTABIOVanta Bioscience Ltd
VANTABIO![](https://assets.tickertape.in/sector-icons/health_care.png)
![](https://assets.tickertape.in/sector-icons/smallcap.png)
![](https://assets.tickertape.in/sector-icons/high_risk.png)
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
— | 1.63 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
49.93 | 6.39 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
The company is a preclinical contract research company. It provides preclinical safety assessment services, assessment services for evaluating the safety of the active pharmaceutical ingredients (API), etc.
Peers
Compare with peersDivi's Laboratories Ltd
Syngene International Ltd
Aarti Pharmalabs Ltd
Dishman Carbogen Amcis Ltd
Vimta Labs Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 0.00 | 4.04 | 12.65 | 14.25 | 10.07 | 10.11 | 6.97 | 9.83 | — | |||||||||
Raw Materials | 0.00 | 2.96 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.41 | — | |||||||||
Power & Fuel Cost | 0.98 | 1.04 | 0.54 | 0.55 | 0.75 | |||||||||||||
Employee Cost | 2.90 | 3.93 | 2.51 | 2.67 | 3.46 | |||||||||||||
Selling & Administrative Expenses | 3.23 | 3.30 | 1.94 | 2.00 | 3.08 | |||||||||||||
Operating & Other expenses | 2.04 | 1.50 | 1.10 | 1.00 | 1.38 | |||||||||||||
EBITDA | 0.00 | 1.08 | 3.50 | 4.48 | 3.98 | 3.89 | -1.70 | 1.42 | — | |||||||||
Depreciation/Amortization | 0.00 | 0.57 | 0.71 | 1.19 | 1.25 | 1.32 | 2.67 | 4.50 | — | |||||||||
PBIT | 0.00 | 0.51 | 2.79 | 3.29 | 2.73 | 2.57 | -4.37 | -3.08 | — | |||||||||
Interest & Other Items | 0.00 | 0.20 | 1.69 | 1.95 | 2.14 | 2.35 | 5.89 | 5.75 | — | |||||||||
PBT | 0.00 | 0.31 | 1.10 | 1.34 | 0.59 | 0.22 | -10.26 | -8.83 | — | |||||||||
Taxes & Other Items | 0.00 | 0.29 | 0.40 | 0.34 | 0.14 | 0.14 | -3.78 | -0.22 | — | |||||||||
Net Income | 0.00 | 0.02 | 0.70 | 1.00 | 0.45 | 0.08 | -6.48 | -8.61 | — | |||||||||
EPS | 0.00 | 0.05 | 1.16 | 1.58 | 0.71 | 0.13 | -10.27 | -3.67 | — | |||||||||
DPS | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | |||||||||
Payout ratio | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CareLabs & Life Sciences Services
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Vanta Bioscience Ltd | -3.59 | 1.63 | — |
Divi's Laboratories Ltd | 83.17 | 9.81 | 0.60% |
Syngene International Ltd | 67.10 | 8.04 | 0.15% |
Aarti Pharmalabs Ltd | 29.23 | 3.61 | 0.43% |
Price Comparison
Compare VANTABIO with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
No institutional holdings trend are available
Shareholding Pattern
Sep 2022
Mar 2023
Sep 2023
Mar 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
VANTABIO has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Vanta Bioscience has postponed the meeting of the Board of Directors which was scheduled to be held on 17 July 2024. The meeting will now be held on 19 July 2024.Powered by Capital Market - Live
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of -4.92%, vs industry avg of 4.63%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.1% to 0.06%